Search
Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodyProducts: SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,1 ADET, SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADETJanssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … As of June 2020, a Phase 1/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity, and efficacy of the ad26.COV.S vaccine in 1045 healthy adults between the ages of 18-55
Synonyms: Ad26.COV2.S, AD26.COV2.S [RECOMBINANT]Cytochrome c oxidase subunit FA4
go.drugbank.com/bio_entities/BE0000169TargetHumansComponent of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII...
Synonyms: Complex I-MLRQParathyroid hormone/parathyroid hormone-related peptide receptor
go.drugbank.com/bio_entities/BE0003508TargetHumansG protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:11773434, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8...
Synonyms: PTH/PTHrP type I receptorIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the
Mixtures: CARIVALAN 25/5, CARIVALAN 6.25/5Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalIt is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. … [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsThrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic … The cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin.
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L39544] It was fully approved by the FDA on May 25, 2023. … [L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. … [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009.
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideFinasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigational[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or
Mixtures: Finasteride 0.1% / Minoxidil 7%, Finasteride 0.1% / Minoxidil 5%Categories: Drugs Used in Benign Prostatic Hypertrophy, 5-alpha Reductase Inhibitors